{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:32:44Z","timestamp":1766050364264,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s11523-023-00976-4","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T10:02:23Z","timestamp":1686650543000},"page":"585-591","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study"],"prefix":"10.1007","volume":"18","author":[{"given":"H\u00e9l\u00e8ne","family":"Babey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Jamme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"Curcio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Baptiste","family":"Assi\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remi","family":"Veillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Doubre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurice","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Guisier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Huchot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantal","family":"Decroisette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel","family":"Falchero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Corre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Cortot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4290-5524","authenticated-orcid":false,"given":"Christos","family":"Choua\u00efd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renaud","family":"Descourt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"key":"976_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.lungcan.2016.11.011","volume":"103","author":"T Reungwetwattana","year":"2017","unstructured":"Reungwetwattana T, Liang Y, Zhu V, Ou S-HI. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the why, the how, the who, the unknown, and the inevitable. Lung Cancer. 2017;103:27\u201337.","journal-title":"Lung Cancer"},{"key":"976_CR2","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.lungcan.2018.07.006","volume":"123","author":"HG Vuong","year":"2018","unstructured":"Vuong HG, Ho ATN, Altibi AMA, Nakazawa T, Katoh R, Kondo T. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer\u2014a systematic review and meta-analysis. Lung Cancer. 2018;123:76\u201382.","journal-title":"Lung Cancer"},{"key":"976_CR3","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1038\/s41388-018-0185-4","volume":"37","author":"L Duplaquet","year":"2018","unstructured":"Duplaquet L, Kherrouche Z, Baldacci S, Jamme P, Cortot AB, Copin M-C, et al. The multiple paths towards MET receptor addiction in cancer. Oncogene. 2018;37:3200\u201315.","journal-title":"Oncogene"},{"key":"976_CR4","doi-asserted-by":"publisher","first-page":"5691","DOI":"10.2147\/OTT.S219959","volume":"13","author":"O Bylicki","year":"2020","unstructured":"Bylicki O, Paleiron N, Assi\u00e9 J-B, Choua\u00efd C. Targeting the MET-signaling pathway in non-small-cell lung cancer: evidence to date. OncoTargets Ther. 2020;13:5691\u2013706.","journal-title":"OncoTargets Ther."},{"key":"976_CR5","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41568-018-0002-y","volume":"18","author":"PM Comoglio","year":"2018","unstructured":"Comoglio PM, Trusolino L, Boccaccio C. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. Nat Rev Cancer. 2018;18:341\u201358.","journal-title":"Nat Rev Cancer"},{"key":"976_CR6","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1038\/s41388-020-1193-8","volume":"39","author":"JP Koch","year":"2020","unstructured":"Koch JP, Aebersold DM, Zimmer Y, Medov\u00e1 M. MET targeting: time for a rematch. Oncogene. 2020;39:2845\u201362.","journal-title":"Oncogene"},{"key":"976_CR7","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1158\/2159-8290.CD-15-0285","volume":"5","author":"GM Frampton","year":"2015","unstructured":"Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015;5:850\u20139.","journal-title":"Cancer Discov"},{"doi-asserted-by":"publisher","unstructured":"Cortot AB, Kherrouche Z, Descarpentries C, Wislez M, Baldacci S, Furlan A, et al. Exon 14 deleted MET receptor as a new biomarker and target in cancers. J Natl Cancer Inst 2017;109(5). https:\/\/doi.org\/10.1093\/jnci\/djw262.","key":"976_CR8","DOI":"10.1093\/jnci\/djw262"},{"key":"976_CR9","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.jtho.2016.06.004","volume":"11","author":"AB Schrock","year":"2016","unstructured":"Schrock AB, Frampton GM, Suh J, Chalmers ZR, Rosenzweig M, Erlich RL, et al. Characterization of 298 patients with lung cancer harboring MET Exon 14 skipping alterations. J Thorac Oncol. 2016;11:1493\u2013502.","journal-title":"J Thorac Oncol"},{"issue":"15_suppl","key":"976_CR10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1200\/JCO.2016.34.15_suppl.108","volume":"34","author":"AE Drilon","year":"2016","unstructured":"Drilon AE, Camidge DR, Ou S-HI, Clark JW, Socinski MA, Weiss J, et al. Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC). J Clin Oncol. 2016;34(15_suppl):108.","journal-title":"J Clin Oncol"},{"key":"976_CR11","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1093\/annonc\/mdz407","volume":"30","author":"D Moro-Sibilot","year":"2019","unstructured":"Moro-Sibilot D, Cozic N, P\u00e9rol M, Mazi\u00e8res J, Otto J, Souquet PJ, et al. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcS\u00e9 phase II trial. Ann Oncol. 2019;30:1985\u201391.","journal-title":"Ann Oncol"},{"key":"976_CR12","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJMoa2004407","volume":"383","author":"PK Paik","year":"2020","unstructured":"Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, et al. Tepotinib in non-small-cell lung cancer with MET Exon 14 skipping mutations. N Engl J Med. 2020;383:931\u201343.","journal-title":"N Engl J Med"},{"key":"976_CR13","first-page":"7312","volume":"25","author":"L Landi","year":"2019","unstructured":"Landi L, Chiari R, Tiseo M, D\u2019Inc\u00e0 F, Dazzi C, Chella A, et al. Crizotinib in MET-DEregulated or ROS1-rearranged pretreated non-small cell lung cancer (METROS): a phase II, prospective. Multicenter Two-Arms Trial Clin Cancer. 2019;25:7312\u20139.","journal-title":"Multicenter Two-Arms Trial. Clin Cancer"},{"key":"976_CR14","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa2002787","volume":"383","author":"J Wolf","year":"2020","unstructured":"Wolf J, Seto T, Han J-Y, Reguart N, Garon EB, Groen HJM, et al. Capmatinib in MET Exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med. 2020;383:944\u201357.","journal-title":"N Engl J Med"},{"key":"976_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.cllc.2022.01.003","volume":"23","author":"A Cortot","year":"2022","unstructured":"Cortot A, Le X, Smit E, Viteri S, Kato T, Sakai H, et al. Safety of MET tyrosine kinase inhibitors in patients with MET Exon 14 skipping non-small cell lung cancer: a clinical review. Clin Lung Cancer. 2022;23:195\u2013207.","journal-title":"Clin Lung Cancer"},{"key":"976_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","volume":"11","author":"P Goldstraw","year":"2016","unstructured":"Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39\u201351.","journal-title":"J Thorac Oncol"},{"key":"976_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"14","key":"976_CR18","first-page":"175","volume":"13","author":"O Illini","year":"2022","unstructured":"Illini O, Fabikan H, Swalduz A, Vikstr\u00f6m A, Krenbek D, Schumacher M, et al. Real-world experience with capmatinib in\u00a0MET\u00a0exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program. Ther Adv Med Oncol. 2022;13(14):175.","journal-title":"Ther Adv Med Oncol."},{"key":"976_CR19","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.lungcan.2019.05.011","volume":"133","author":"MM Awad","year":"2019","unstructured":"Awad MM, Leonardi GC, Kravets S, Dahlberg SE, Drilon A, Noonan SA, et al. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung Cancer. 2019;133:96\u2013102.","journal-title":"Lung Cancer"},{"key":"976_CR20","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","volume":"30","author":"J Mazieres","year":"2019","unstructured":"Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;30:1321\u20138.","journal-title":"Ann Oncol"},{"key":"976_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.lungcan.2020.09.008","volume":"150","author":"M Mayenga","year":"2020","unstructured":"Mayenga M, Assi\u00e9 J-B, Monnet I, Massiani M-A, Tabeze L, Friard S, et al. Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14\u2013skipping mutation: a series of 6 cases. Lung Cancer. 2020;150:21\u20135.","journal-title":"Lung Cancer"},{"key":"976_CR22","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s10147-021-01893-0","volume":"26","author":"Y Kato","year":"2021","unstructured":"Kato Y, Yamamoto G, Watanabe Y, Yamane Y, Mizutani H, Kurimoto F, et al. Long-term efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring MET exon 14 skipping mutations. Int J Clin Oncol. 2021;26:1065\u201372.","journal-title":"Int J Clin Oncol"},{"key":"976_CR23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"J-C Soria","year":"2018","unstructured":"Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113\u201325.","journal-title":"N Engl J Med"},{"key":"976_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41\u201350.","journal-title":"N Engl J Med"},{"key":"976_CR25","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim D-W, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377:829\u201338.","journal-title":"N Engl J Med"},{"doi-asserted-by":"crossref","unstructured":"Drilon A, Clark JW, Weiss J, Ou S-HI, Camidge DR, Solomon BJ, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med 2020;26:47\u201151.","key":"976_CR26","DOI":"10.1038\/s41591-019-0716-8"},{"key":"976_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.lungcan.2021.06.015","volume":"159","author":"M Bittoni","year":"2021","unstructured":"Bittoni M, Yang JC, Shih JY. et a; Real-world insights into patients with advanced NSCLC and MET alterations. Lung Cancer. 2021;159:96\u2013106.","journal-title":"Lung Cancer"},{"key":"976_CR28","first-page":"PO.21.00122","volume":"5","author":"JK Lee","year":"2021","unstructured":"Lee JK, Madison R, Classon A. Characterization of non-small-cell lung cancers with MET Exon 14 skipping alterations detected in tissue or liquid: clinicogenomics and real-world treatment patterns. JCO Precis Oncol. 2021;5:PO.21.00122.","journal-title":"JCO Precis Oncol"},{"key":"976_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107677","volume":"9","author":"A Dimou","year":"2014","unstructured":"Dimou A, Non L, Chae YK, Tester WJ, Syrigos KN. MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC); a systematic review and meta-analysis. PLoS ONE. 2014;9: e107677.","journal-title":"PLoS ONE"},{"key":"976_CR30","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.7150\/jca.24980","volume":"9","author":"JH Kim","year":"2018","unstructured":"Kim JH, Kim HS, Kim BJ. Prognostic value of MET copy number gain in non-small-cell lung cancer: an updated meta-analysis. J Cancer. 2018;9:1836\u201345.","journal-title":"J Cancer"},{"issue":"15_suppl","key":"976_CR31","doi-asserted-by":"publisher","first-page":"9062","DOI":"10.1200\/JCO.2018.36.15_suppl.9062","volume":"36","author":"DR Camidge","year":"2018","unstructured":"Camidge DR, Otterson GA, Clark JW, Ou S-HI, Weiss J, Ades S, et al. Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial. J Clin Oncol. 2018;36(15_suppl):9062.","journal-title":"J Clin Oncol"},{"key":"976_CR32","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","volume":"34","author":"MM Awad","year":"2016","unstructured":"Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, et al. MET Exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression. J Clin Oncol. 2016;34:721\u201330.","journal-title":"J Clin Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-00976-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-023-00976-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-00976-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T10:20:01Z","timestamp":1689243601000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-023-00976-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["976"],"URL":"https:\/\/doi.org\/10.1007\/s11523-023-00976-4","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"type":"print","value":"1776-2596"},{"type":"electronic","value":"1776-260X"}],"subject":[],"published":{"date-parts":[[2023,6,13]]},"assertion":[{"value":"10 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by the Groupe fran\u00e7ais de Pneumo Oncologie, an academic research group.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"H\u00e9l\u00e8ne Babey, Philippe Jamme, Hubert Curcio, Jean Baptiste Assi\u00e9, Remi Veillon, H\u00e9l\u00e8ne Doubre, Maurice P\u00e9rol, Florian Guisier, Eric Huchot, Chantal Decroisette, Lionel Falchero, Romain Corre, Alexis Cortot, Christos Chouaid, and Renaud Descourt declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the French Advisory Committee on Information Processing in Health Research (CCTIRS). Living patients were informed and gave their non-objection to participate in the study, and for deceased patients, an exemption of information was obtained.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"HB, CC, and HC conceived, designed the study, and wrote the paper. JBA, RV, HD, MP, FG, RH, CD, LF, AMC, MA, and AC revised the paper for important intellectual content. All authors read and approved the final manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}